Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Veracyte, Inc.    VCYT

VERACYTE, INC.

(VCYT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Veracyte, Inc. is a genomic diagnostics company. The Company, through its scientific platform, which utilizes ribonucleic acid (RNA), whole-transcriptome sequencing combined with machine learning, produces genomic tests. It provides various genomic tests, including Afirma Genomic Sequencing Classifier (GSC), Percepta Bronchial Genomic Classifier, Envisia Genomic Classifier and Afirma Xpression Atlas. It provides GSC tests for thyroid cancer. It provides Percepta Bronchial Genomic Classifier tests for lung cancer. It provides Envisia Genomic Classifier tests for idiopathic pulmonary fibrosis (IPF). Its Afirma Xpression Atlas provides information on gene alterations associated with thyroid cancer, enabling physicians to tailor surgical and treatment decisions at time of diagnosis.

Number of employees : 270 people.
Sales per Businesses
20172018Delta
USD (in Million)%USD (in Million)%
Genomic Diagnostics71.95100%92.01100% +27.87%
Sales per Regions
20172018Delta
USD (in Million)%USD (in Million)%
United States71.95100%92.01100% +27.87%
Managers
NameAgeSinceTitle
Bonnie H. Anderson612017Chairman & Chief Executive Officer
Keith Kennedy492019Chief Operating & Financial Officer
Giulia C. Kennedy, Dr.592018Chief Scientific & Medical Officer
Ashish Kheterpal-2016Chief Information Officer
Fred E. Cohen, Dr.622007Independent Director
Evan Jones622008Independent Director
Karin Eastham692012Independent Director
John L. Bishop742016Lead Independent Director
Robert S. Epstein, Dr.632015Independent Director
Tina Susan Nova, Dr.662015Independent Director
Equities
Vote QuantityFloatCompany-owned sharesTotal Float
Stock A 1 48,840,294 48,140,326 98.6% 0 0.0% 98.6%
Shareholders
NameEquities%
Gilder, Gagnon, Howe & Co. LLC 3,824,626 7.83%
Invesco Advisers, Inc. 2,977,145 6.10%
Nikko Asset Management Americas, Inc. 2,764,236 5.66%
Nikko Asset Management Co., Ltd. 2,764,236 5.66%
ARK Investment Management LLC 2,582,798 5.29%
The Vanguard Group, Inc. 2,447,067 5.01%
Versant Venture Management LLC 2,410,814 4.94%
SSgA Funds Management, Inc. 2,115,754 4.33%
BlackRock Fund Advisors 1,567,362 3.21%
Domain Associates LLC 1,231,647 2.52%
Company contact information
Veracyte, Inc.
6000 Shoreline Court
Suite 300
South San Francisco, CA 94080

Phone : +1.650.243.6300
Fax : +1.650.243.6301
Web : http://www.veracyte.com
Sector Bio Diagnostics & Testing
1st jan.Capitalization (M$)
VERACYTE, INC.7.99%1 473
GUARDANT HEALTH, INC.8.27%7 944
GENSCRIPT BIOTECH CORPORATION6.09%4 551
IOVANCE BIOTHERAPEUTICS, INC.-13.75%3 013
INVITAE CORPORATION21.70%1 895
MIRACA HOLDINGS INC.1.69%1 402
CAREDX, INC9.46%1 002
SEEGENE INC--.--%695
INNATE PHARMA15.02%597
EPIGENOMICS AG4.03%69
LYSOGENE63.64%45
Connections : Veracyte, Inc.